Zacks Investment Research cut shares of BeyondSpring Inc. (NASDAQ:BYSI) from a hold rating to a sell rating in a research report sent to investors on Monday morning.
According to Zacks, “BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company’s lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. “
Other research analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a buy rating and set a $50.00 target price on shares of BeyondSpring in a research note on Monday, August 21st. Maxim Group reaffirmed a buy rating and set a $52.00 target price on shares of BeyondSpring in a research note on Friday, October 27th.
Shares of BeyondSpring (BYSI) traded down $0.68 during mid-day trading on Monday, reaching $34.83. The company had a trading volume of 1,000 shares, compared to its average volume of 5,758. BeyondSpring has a fifty-two week low of $16.55 and a fifty-two week high of $48.49.
BeyondSpring (NASDAQ:BYSI) last announced its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.01. equities analysts forecast that BeyondSpring will post -4.41 EPS for the current fiscal year.
An institutional investor recently bought a new position in BeyondSpring stock. Tanaka Capital Management Inc. purchased a new stake in BeyondSpring Inc. (NASDAQ:BYSI) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring accounts for approximately 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th biggest position. Tanaka Capital Management Inc. owned 0.10% of BeyondSpring as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 1.23% of the company’s stock.
BeyondSpring Company Profile
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with MarketBeat.com's FREE daily email newsletter.